Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LARP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LARP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LARP1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LARP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LARP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LARP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LARP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LARP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LARP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001907917 | Endometrium | EEC | viral genome replication | 42/2168 | 131/18723 | 3.43e-10 | 3.61e-08 | 42 |
GO:003133117 | Endometrium | EEC | positive regulation of cellular catabolic process | 94/2168 | 427/18723 | 4.30e-10 | 4.45e-08 | 94 |
GO:000640215 | Endometrium | EEC | mRNA catabolic process | 60/2168 | 232/18723 | 1.17e-09 | 9.92e-08 | 60 |
GO:000640115 | Endometrium | EEC | RNA catabolic process | 65/2168 | 278/18723 | 1.90e-08 | 1.16e-06 | 65 |
GO:000641717 | Endometrium | EEC | regulation of translation | 94/2168 | 468/18723 | 5.37e-08 | 2.88e-06 | 94 |
GO:004572716 | Endometrium | EEC | positive regulation of translation | 38/2168 | 136/18723 | 1.47e-07 | 6.89e-06 | 38 |
GO:003425016 | Endometrium | EEC | positive regulation of cellular amide metabolic process | 42/2168 | 162/18723 | 3.24e-07 | 1.32e-05 | 42 |
GO:190165416 | Endometrium | EEC | response to ketone | 46/2168 | 194/18723 | 1.44e-06 | 4.64e-05 | 46 |
GO:000644614 | Endometrium | EEC | regulation of translational initiation | 25/2168 | 79/18723 | 1.62e-06 | 5.03e-05 | 25 |
GO:005079217 | Endometrium | EEC | regulation of viral process | 40/2168 | 164/18723 | 3.24e-06 | 8.85e-05 | 40 |
GO:006101313 | Endometrium | EEC | regulation of mRNA catabolic process | 40/2168 | 166/18723 | 4.47e-06 | 1.14e-04 | 40 |
GO:003133017 | Endometrium | EEC | negative regulation of cellular catabolic process | 55/2168 | 262/18723 | 7.93e-06 | 1.80e-04 | 55 |
GO:004348813 | Endometrium | EEC | regulation of mRNA stability | 38/2168 | 158/18723 | 8.03e-06 | 1.81e-04 | 38 |
GO:190390017 | Endometrium | EEC | regulation of viral life cycle | 36/2168 | 148/18723 | 1.05e-05 | 2.25e-04 | 36 |
GO:004427013 | Endometrium | EEC | cellular nitrogen compound catabolic process | 83/2168 | 451/18723 | 1.17e-05 | 2.43e-04 | 83 |
GO:004670013 | Endometrium | EEC | heterocycle catabolic process | 82/2168 | 445/18723 | 1.26e-05 | 2.55e-04 | 82 |
GO:003465514 | Endometrium | EEC | nucleobase-containing compound catabolic process | 76/2168 | 407/18723 | 1.61e-05 | 3.12e-04 | 76 |
GO:004348713 | Endometrium | EEC | regulation of RNA stability | 39/2168 | 170/18723 | 1.99e-05 | 3.60e-04 | 39 |
GO:190331217 | Endometrium | EEC | negative regulation of mRNA metabolic process | 25/2168 | 92/18723 | 3.19e-05 | 5.51e-04 | 25 |
GO:001943913 | Endometrium | EEC | aromatic compound catabolic process | 83/2168 | 467/18723 | 4.32e-05 | 7.10e-04 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP1 | SNV | Missense_Mutation | novel | c.1336N>T | p.Arg446Cys | p.R446C | Q6PKG0 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
LARP1 | SNV | Missense_Mutation | | c.2636N>T | p.Arg879Leu | p.R879L | Q6PKG0 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
LARP1 | SNV | Missense_Mutation | | c.2360N>T | p.Cys787Phe | p.C787F | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | | c.498N>C | p.Gln166His | p.Q166H | Q6PKG0 | protein_coding | tolerated(0.06) | benign(0.048) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LARP1 | SNV | Missense_Mutation | | c.1789N>A | p.Glu597Lys | p.E597K | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | rs775862354 | c.253C>T | p.Arg85Cys | p.R85C | Q6PKG0 | protein_coding | deleterious(0) | possibly_damaging(0.809) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | | c.1676N>T | p.Asp559Val | p.D559V | Q6PKG0 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LARP1 | SNV | Missense_Mutation | novel | c.238N>A | p.Ala80Thr | p.A80T | Q6PKG0 | protein_coding | tolerated(0.08) | possibly_damaging(0.677) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
LARP1 | insertion | Nonsense_Mutation | novel | c.768_769insTGAAGTC | p.Arg257Ter | p.R257* | Q6PKG0 | protein_coding | | | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LARP1 | insertion | Frame_Shift_Ins | novel | c.815_816insCCCAGAGAGAAACTGGCTTC | p.Arg273ProfsTer38 | p.R273Pfs*38 | Q6PKG0 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |